DNA graphic

Glossary: Belimumab (Benlysta)

In 2011, the FDA approved belimumab (Benlysta®), a B-lymphocyte stimulator (BLyS) protein inhibitor, for adult patients with active, autoantibody-positive, systemic lupus erythematosus who are receiving  standard therapies. Given by IV infusion, belimumab may reduce the number of abnormal B cells thought to be a problem in lupus.

In July 2017, belimumab (Benlysta®), was approved by U.S. Food and Drug Administration as a self-injectable (subcutaneous) formulation for people with systemic lupus erythematosus being treated with standard therapy. The new formulation allows patients to administer the drug to themselves as a once-weekly injection.

Source: FDA.gov

View Full Glossary

Together, ManyOne Can make a difference!